Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Earlier this year, doctors at Veterans Affairs hospitals in Pennsylvania sounded an alarm. Sweeping cuts imposed by the Trump ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

April is Head and Cancer Awareness Month, and the Georgia Cancer Center held free screenings Friday. It’s a process that ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Young women are at a higher risk of cancer than men. This alarm was raised at the conference organized by the Mohre ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Adding pembrolizumab before and after surgery reduced recurrence and improved response in patients with locally advanced head ...

Low-dose computed tomography is more sensitive than chest radiography in detecting lung metastases or second primary lung cancer in patients with HNSCC.

Immutep Ltd. announced strong median overall survival of 17.6 months in cohort B of the TACTI-003 (Keynote-PNC-34) phase IIb ...

Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients. The Australian cancer-treatment company said Monday the median rate for overall ...

FDA meeting requested following Phase IIb trial showing median overall survival of 17.6 months without chemotherapy Immutep ...